UBS Turns More Bullish on Gilead Sciences, Inc. (GILD) Amid Positive Pharma Sector Outlook [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Sciences, Inc. (NASDAQ:GILD) from $145 to $155 and maintained a Buy rating, according to TheFly. Slightly below the consensus 1-year high price target, the revised target implies nearly 12% upside. From appealing valuations and light positioning to supporting drug-pricing overhangs and sustained pharma-led M&A activity, there are many reasons to believe in the strong performance of the U.S. Pharmaceuticals and Biotechnology group, the analyst noted. UBS noted that although there are worries regarding the conservative guidance, particularly after the recent rally, inexpensive valuations for big pharma and biotech are expected to continue positive money flows into the sector. Copyright: dolgachov / 123RF Stock Photo On the same day, BMO Capital also raised its target on Gilead Sciences, Inc. (NASDAQ:GILD) to $150 from $135 and reiterated an Outperform rating on the stock. While highlighting the Yeztugo launch, which achieved $150 million in FY25 sales, the firm cited strong moment
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences, Inc. (GILD): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Leerink Partners from $114.00 to $146.00. They now have an "outperform" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at TD Cowen from $125.00 to $145.00. They now have a "buy" rating on the stock.MarketBeat
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 1/29/26 - Form 4
- 1/28/26 - Form 144
- 1/26/26 - Form 4
- GILD's page on the SEC website